Greater Boston prides itself on being a biopharmaceutical hotbed, but a new report suggests that the Chinese are also keenly interested in the life sciences industry.
The report is from Lux Research, a Boston-based firm that seeks to provides strategic advice and intelligence for emerging technologies.
Commenting on the report, a Lux Research press release said, “A clutch of promising Chinese companies in the formulation and delivery (F/D) market underlines the emergence of the Asian giant as a center for biopharma innovation and entrepreneurship, even as Western pharmaceutical companies continue to enjoy technological and business advantages.”
